Insulet Expands Omnipod® 5 to Four More International Markets
Insulet (NASDAQ: PODD) has announced the expansion of its Omnipod 5 Automated Insulin Delivery System to four new international markets. The system is now commercially available in Australia with Dexcom G6 and G7 compatibility, and will soon launch in Belgium, Canada, and Switzerland.
The tubeless insulin delivery system features SmartAdjust™ technology that automatically adjusts insulin delivery every five minutes. In Australia, plans are underway to add Abbott's FreeStyle Libre® 2 Plus compatibility. Belgium will have access to both Abbott's FreeStyle Libre 2 Plus and Dexcom G6/G7 integrations. Canada and Switzerland launches are scheduled for spring, with varying sensor compatibilities.
Additionally, Insulet plans to expand to five more markets including Israel, Saudi Arabia, UAE, Qatar, and Kuwait, with timing to be announced. The company recently added Dexcom G7 integration for Omnipod 5 users in the UK and Netherlands.
Insulet (NASDAQ: PODD) ha annunciato l'espansione del suo Omnipod 5 Sistema di Somministrazione Automatica di Insulina in quattro nuovi mercati internazionali. Il sistema è ora disponibile commercialmente in Australia con compatibilità con Dexcom G6 e G7, e presto sarà lanciato in Belgio, Canada e Svizzera.
Il sistema di somministrazione di insulina senza tubi presenta la tecnologia SmartAdjust™ che regola automaticamente la somministrazione di insulina ogni cinque minuti. In Australia, sono in programma aggiunte per la compatibilità con il FreeStyle Libre® 2 Plus di Abbott. Il Belgio avrà accesso sia al FreeStyle Libre 2 Plus di Abbott che alle integrazioni Dexcom G6/G7. I lanci in Canada e Svizzera sono previsti per la primavera, con diverse compatibilità dei sensori.
Inoltre, Insulet prevede di espandersi in altri cinque mercati, tra cui Israele, Arabia Saudita, Emirati Arabi Uniti, Qatar e Kuwait, con tempistiche da annunciare. L'azienda ha recentemente aggiunto l'integrazione con Dexcom G7 per gli utenti di Omnipod 5 nel Regno Unito e nei Paesi Bassi.
Insulet (NASDAQ: PODD) ha anunciado la expansión de su Sistema de Entrega Automática de Insulina Omnipod 5 a cuatro nuevos mercados internacionales. El sistema ya está disponible comercialmente en Australia con compatibilidad con Dexcom G6 y G7, y pronto se lanzará en Bélgica, Canadá y Suiza.
El sistema de entrega de insulina sin tubos cuenta con la tecnología SmartAdjust™ que ajusta automáticamente la entrega de insulina cada cinco minutos. En Australia, se están realizando planes para añadir la compatibilidad con el FreeStyle Libre® 2 Plus de Abbott. Bélgica tendrá acceso tanto al FreeStyle Libre 2 Plus de Abbott como a las integraciones Dexcom G6/G7. Los lanzamientos en Canadá y Suiza están programados para la primavera, con diferentes compatibilidades de sensores.
Además, Insulet planea expandirse a cinco mercados más, incluidos Israel, Arabia Saudita, Emiratos Árabes Unidos, Qatar y Kuwait, con tiempos a anunciar. La compañía recientemente agregó la integración con Dexcom G7 para los usuarios de Omnipod 5 en el Reino Unido y los Países Bajos.
인슐렛 (NASDAQ: PODD)는 Omnipod 5 자동 인슐린 전달 시스템을 네 개의 새로운 국제 시장으로 확장한다고 발표했습니다. 이 시스템은 이제 호주에서 Dexcom G6 및 G7과 호환되어 상업적으로 이용 가능하며, 곧 벨기에, 캐나다 및 스위스에서 출시될 예정입니다.
튜브 없는 인슐린 전달 시스템은 5분마다 인슐린 전달을 자동으로 조정하는 SmartAdjust™ 기술을 특징으로 합니다. 호주에서는 Abbott의 FreeStyle Libre® 2 Plus와의 호환성을 추가할 계획이 진행 중입니다. 벨기에는 Abbott의 FreeStyle Libre 2 Plus와 Dexcom G6/G7 통합에 접근할 수 있습니다. 캐나다와 스위스의 출시는 봄으로 예정되어 있으며, 다양한 센서 호환성이 있습니다.
또한, 인슐렛은 이스라엘, 사우디아라비아, 아랍에미리트, 카타르 및 쿠웨이트를 포함한 다섯 개의 추가 시장으로 확장할 계획이며, 일정은 추후 발표될 예정입니다. 이 회사는 최근 영국과 네덜란드의 Omnipod 5 사용자에게 Dexcom G7 통합을 추가했습니다.
Insulet (NASDAQ: PODD) a annoncé l'expansion de son Système de Livraison Automatique d'Insuline Omnipod 5 dans quatre nouveaux marchés internationaux. Le système est maintenant disponible commercialement en Australie avec compatibilité Dexcom G6 et G7, et sera bientôt lancé en Belgique, Canada et Suisse.
Le système de livraison d'insuline sans tube dispose de la technologie SmartAdjust™ qui ajuste automatiquement la livraison d'insuline toutes les cinq minutes. En Australie, des plans sont en cours pour ajouter la compatibilité avec le FreeStyle Libre® 2 Plus d'Abbott. La Belgique aura accès à la fois au FreeStyle Libre 2 Plus d'Abbott et aux intégrations Dexcom G6/G7. Les lancements au Canada et en Suisse sont prévus pour le printemps, avec des compatibilités de capteurs variées.
De plus, Insulet prévoit de s'étendre à cinq autres marchés, y compris Israël, l'Arabie Saoudite, les Émirats Arabes Unis, le Qatar et le Koweït, avec un calendrier à annoncer. L'entreprise a récemment ajouté l'intégration de Dexcom G7 pour les utilisateurs d'Omnipod 5 au Royaume-Uni et aux Pays-Bas.
Insulet (NASDAQ: PODD) hat die Expansion seines Omnipod 5 Automatisches Insulin-Abgabesystems auf vier neue internationale Märkte angekündigt. Das System ist jetzt kommerziell in Australien mit Kompatibilität zu Dexcom G6 und G7 erhältlich und wird bald in Belgien, Kanada und der Schweiz eingeführt.
Das tubeless Insulin-Abgabesystem verfügt über die SmartAdjust™-Technologie, die die Insulinabgabe alle fünf Minuten automatisch anpasst. In Australien sind Pläne im Gange, die Kompatibilität mit Abbotts FreeStyle Libre® 2 Plus hinzuzufügen. Belgien wird sowohl Zugang zu Abbotts FreeStyle Libre 2 Plus als auch zu Dexcom G6/G7-Integrationen haben. Die Einführungen in Kanada und der Schweiz sind für den Frühling geplant, mit unterschiedlichen Sensor-Kompatibilitäten.
Darüber hinaus plant Insulet, sich auf fünf weitere Märkte, darunter Israel, Saudi-Arabien, die VAE, Katar und Kuwait, auszudehnen, wobei der Zeitpunkt noch bekannt gegeben wird. Das Unternehmen hat kürzlich die Integration von Dexcom G7 für Omnipod 5-Nutzer im Vereinigten Königreich und in den Niederlanden hinzugefügt.
- Significant international market expansion to four new countries
- Multiple sensor compatibility options (Dexcom G6/G7 and Abbott FreeStyle Libre 2 Plus)
- Plans for further expansion into five Middle Eastern markets
- Recently completed successful launches in major markets including US, UK, Germany, France
- Exact launch timing for Middle Eastern markets remains uncertain
- Varying sensor compatibility across different regions may limit initial adoption
Insights
Insulet's expansion of Omnipod 5 into Australia, Belgium, Canada, and Switzerland represents a significant growth catalyst that strengthens the company's international footprint. This phased rollout continues the momentum following successful launches in major markets including the U.S., UK, Germany, and France.
What makes this expansion particularly strategic is the integration with multiple CGM technologies (Dexcom G6/G7 and Abbott's FreeStyle Libre 2 Plus) across these regions. This interoperability significantly broadens Insulet's addressable market by ensuring compatibility with whichever CGM system patients prefer or is predominant in each region.
The announcement of five additional planned markets (Israel, Saudi Arabia, UAE, Qatar, Kuwait) indicates Insulet's systematic approach to global expansion. This methodical geographical rollout suggests the company has established effective pathways for navigating international regulatory frameworks and reimbursement systems.
From a competitive standpoint, Omnipod 5's unique tubeless design and smartphone control capabilities continue to differentiate it from traditional pumps offered by competitors like Medtronic and Tandem. The emphasis on being the "only tubeless commercial AID System" underscores this key competitive advantage as Insulet enters new territories.
For shareholders, this expansion directly translates to potential revenue growth by increasing the total addressable patient population. The diabetes management device market remains relatively underpenetrated internationally, offering substantial growth runway for Insulet's flagship product.
The international expansion of Omnipod 5 represents meaningful clinical progress for diabetes management. The technology addresses several persistent challenges in insulin-dependent diabetes care through its automated insulin delivery approach.
The system's SmartAdjust™ technology, which makes automatic adjustments every five minutes, represents significant advancement over traditional insulin delivery methods. This continuous automated correction helps prevent both hyperglycemic and hypoglycemic events - a critical balance that patients struggle to maintain with multiple daily injections.
Particularly noteworthy is the impact for pediatric patients, as highlighted by the Australian parent testimonial. For children like five-year-old Priya, the tubeless design and automated delivery significantly reduces the burden of diabetes management during school and social activities, addressing important quality-of-life considerations that extend beyond clinical metrics.
The Canadian endocrinologist's reference to new Diabetes Canada Guidelines that "all people with type 1 diabetes should use an AID System" underscores the clinical consensus forming around automated systems as the standard of care. This alignment with evolving treatment guidelines positions Omnipod 5 favorably as it enters these new markets.
The upcoming presentation at the International Conference on Advanced Technologies & Treatments for Diabetes assessing direct transition from multiple daily injections to Omnipod 5 is significant. If positive, this data could accelerate adoption by demonstrating successful transition without intermediate steps, potentially expanding the immediate candidate pool for the system in these new markets.
The Omnipod 5 Automated Insulin Delivery System is now commercially available in
-
Omnipod 5 is now commercially available in
Australia with Dexcom G6 and G7 compatibility, with plans underway to soon add Abbott’s FreeStyle Libre® 2 Plus. -
Omnipod 5 will be accessible in
Belgium in the coming weeks, with Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 and G7 sensor integrations. -
Omnipod 5 will next launch in
Canada later this spring with Dexcom G6 and G7 compatibility. -
Omnipod 5 will also be offered in
Switzerland , also later this spring, with Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 and G7 sensor integrations.
Insulet also recently expanded sensor integrations to include Dexcom G7 for Omnipod 5 users in the
“Bringing our life-changing flagship Omnipod 5 to people living with diabetes in these four new countries is both incredibly exciting and meaningful, further cementing our leadership position worldwide,” said Pat Crannell, Senior Vice President and International General Manager. “We’re transforming diabetes management, delivering real-world benefits for our customers to help make diabetes a smaller part of their busy lives.”
The Omnipod 5 System simplifies diabetes management and has shown to improve clinical outcomes by eliminating the need for multiple daily injections (MDI) and automatically adjusting insulin delivery every five minutes using its advanced SmartAdjust™ technology. The waterproof 1, discreet, and wearable Omnipod 5 is the first tubeless AID system that communicates with a continuous glucose monitor, proactively correcting for highs and helping to protect against lows, day and night 2,3.
Kimmie Patel, who lives in
“Canadians living with type 1 diabetes have been anxiously awaiting the arrival of Omnipod 5, the only tubeless commercial AID System. In keeping with our new Diabetes Canada Guidelines that all people with type 1 diabetes should use an AID System, the arrival of Omnipod 5 will be life changing for many people living with diabetes and their families,” said Dr. Ilana Halperin, an endocrinologist at Sunnybrook Health Sciences Centre in
Today’s announcement was made before the 18th International Conference on Advanced Technologies & Treatments for Diabetes, where the Company will present new clinical data assessing the direct transition from multiple daily injections to Omnipod 5 in adults and children with type 1 diabetes.
This news follows Insulet’s announcement in January about Omnipod 5 launches
1 The Pod has an IP28 rating for up to 7.6 meters (25 feet) for 60 minutes. The Omnipod 5 Controller is not waterproof. |
2 Sherr JL, et al. Diabetes Care (2022). Study in 80 people with type 1 diabetes (T1D) aged 2 - 5.9 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode. |
3 Brown et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode. |
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in
Forward-Looking Statement:
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 21, 2025 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary materially from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250318667064/en/
Investor Relations:
June Lazaroff
Senior Director, Investor Relations
(978) 600-7717
jlazaroff@insulet.com
Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com
Source: Insulet Corporation